In a strategic move to enhance the ophthalmology portfolio, Lupin, entered into a licensing and supply agreement with Huons, a Korean pharmaceutical firm. The partnership aims to facilitate the registration and marketing of cyclosporine ophthalmic nanoemulsion in Mexico.
Cyclosporine ophthalmic nanoemulsion, a preservative-free solution, is designed to treat dry eye syndrome and promote the healing of corneal ulcers. By utilizing nanotechnology, this treatment provides rapid symptom relief by boosting tear production in patients with reduced tear formation.
Already approved in South Korea, Peru, and various Middle Eastern nations, the product represents a significant advancement for Huons. Yohun Aum, Senior Director and Head of the Global Business Division at Huons stated, “We look forward to a strong partnership in supplying high-quality products for the Mexican market”.
Lupin develops and markets a broad spectrum of branded and generic medications, including biotechnology products and active pharmaceutical ingredients (APIs), across over 100 global markets.
As reported by business-standard.com, the company holds leading positions in cardiology, anti-diabetes, and respiratory treatments, with a notable presence in other therapeutic areas. As the third-largest pharmaceutical company in the US by prescriptions, Lupin consistently invests heavily in research and development to drive innovation and growth.
